Home Online Features Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction
Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction
Press Releases
Keen Vision Acquisition Corporation, Medera Inc., Keen Vision Acquisition Corporation; Medera Inc.  
October 24, 2024

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing over US$100B per yearHeart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all

logo salamanca press

Salamanca Press

email salamanca press
Local & Social